Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator.
نویسنده
چکیده
ISSUE A novel mechanism of action has recently been described for levetiracetam, a member of a new class of anticonvulsants. Levetiracetam binds selectively and with high affinity to a synaptic vesicle protein known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.
منابع مشابه
Levetiracetam.
Levetiracetam (LEV) is a novel antiepileptic drug (AED) which was discovered in early 1980s and soon, in 1999 FDA approved LEV for the management of partial onset seizure. In India, LEV tablet was approved in April 2005. It acts by binding to the synaptic vesicle protein SV2A, which is present on synaptic vesicles and some neuroendocrine cells. Pharmacokinetics of LEV such as, less protein bind...
متن کاملLevetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
Levetiracetam is an FDA-approved drug used to treat epilepsy and other disorders of the nervous system. Although it is known that levetiracetam binds the synaptic vesicle protein SV2A, how drug binding affects synaptic functioning remains unknown. Here we report that levetiracetam reverses the effects of excess SV2A in autaptic hippocampal neurons. Expression of an SV2A-EGFP fusion protein prod...
متن کاملA new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam.
Levetiracetam (LEV) is one of the most commonly prescribed antiepileptic drugs, but its mechanism of action is uncertain. Based on prior information that LEV binds to the vesicular protein synaptic vesicle protein 2A and reduces presynaptic neurotransmitter release, we wanted to more rigorously characterize its effect on transmitter release and explain the requirement for a prolonged incubation...
متن کاملSynaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
The synaptic vesicle glycoprotein SV2A belongs to the major facilitator superfamily (MFS) of transporters and is an integral constituent of synaptic vesicle membranes. SV2A has been demonstrated to be involved in vesicle trafficking and exocytosis, processes crucial for neurotransmission. The anti-seizure drug levetiracetam was the first ligand to target SV2A and displays a broad spectrum of an...
متن کاملVesicular Entry May Mediate the Effects of Levetiracetam
29 Levetiracetam (LEV) is one of the most commonly prescribed antiepileptic drugs, but its 30 mechanism of action is uncertain. Based upon prior information that LEV binds to the vesicular 31 protein Synaptic Vesicle Protein 2A (SV2A) and reduces presynaptic neurotransmitter release, 32 we wanted to more rigorously characterize its effect on transmitter release and explain the 33 requirement fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of clinical psychiatry
دوره 65 9 شماره
صفحات -
تاریخ انتشار 2004